Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
The Team
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Platform
SubB2M Platform
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Resources
Business Development
Products
Our Products
EXO-NET® Pan-Exosome
Product Overview
Technical Information
Data & Figures
Ordering
hTERT ICC Test
Pipeline
Development Pipeline
NeuCA15-3 Test
NeuCA125 Test
EXO-Ovarian Cancer Test
Exosome Therapeutics
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
News & Events
INOVIQ in the News
Conferences & Events
Contact
Contact Us
Subscribe to Email Alerts
ASX Announcements
Heading &
Sub-heading can be edited through HQI
Investors
>
ASX Announcements
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
16-Dec-2024
Weaponising Exosomes for Breast Cancer treatment
11-Dec-2024
Investor Webinar Presentation
5-Dec-2024
Disease Specificity study completed for NeuCA15-3 test
3-Dec-2024
EXO-OC test delivers outstanding performance
28-Nov-2024
2024 AGM Results of Meeting
28-Nov-2024
2024 AGM CEO Presentation
26-Nov-2024
INOVIQ receives $1m RDTI refund
31-Oct-2024
Quarterly Business Update and Appendix 4C - September 2024
25-Oct-2024
Notice of Annual General Meeting/Proxy Form
20-Sep-2024
2024 Annual Report
1
2
3
4
Next
